(Total Views: 445)
Posted On: 02/24/2017 7:56:30 PM
Post# of 72440
It's absurd for those bashers to claim that a salary of a few hundred thousand a year is more important to the CTIX management than the value of the MILLIONS of shares they own. Ehrlich and Menon are the two largest shareholders by far. Every buck the stock goes up, or drops, means a difference of many millions of dollars to these guys.
5 clinical trials, for 5 different applications of 3 distinctly different drugs.
Market cap: 115 million.
Let's look at AVXL, with one drug in Alzheimer's trial (notoriously difficult and lengthy clinical trial process) -- market cap, just under 233 million. Months before any meaningful results from its very small first study.
AXON, a failed Alzheimer's drug that they bought for 5 million bucks and are trying new clinical trials yet again:
market cap 1.16 Billion. Yes, billion.
ARTH (disclosure: I own and like this stock), one platform, a surgical glue that is faster setting and dries transparent so the surgeon can see what's going on, early stage clinical trials, market cap 94.27 million.
So riskier and previous failed drugs warrant company market caps that are 2-10 times higher than CTIX, and ARTH is at about 80% of the market cap of a company with 5 clinical trials that are further along than ARTH's one trial.
Uh-huh.
The only thing wrong with CTIX is that bashing articles and syndicates of pumper/dumper gangs have attacked it. I am totally confident in my very large investment here.
5 clinical trials, for 5 different applications of 3 distinctly different drugs.
Market cap: 115 million.
Let's look at AVXL, with one drug in Alzheimer's trial (notoriously difficult and lengthy clinical trial process) -- market cap, just under 233 million. Months before any meaningful results from its very small first study.
AXON, a failed Alzheimer's drug that they bought for 5 million bucks and are trying new clinical trials yet again:
market cap 1.16 Billion. Yes, billion.
ARTH (disclosure: I own and like this stock), one platform, a surgical glue that is faster setting and dries transparent so the surgeon can see what's going on, early stage clinical trials, market cap 94.27 million.
So riskier and previous failed drugs warrant company market caps that are 2-10 times higher than CTIX, and ARTH is at about 80% of the market cap of a company with 5 clinical trials that are further along than ARTH's one trial.
Uh-huh.
The only thing wrong with CTIX is that bashing articles and syndicates of pumper/dumper gangs have attacked it. I am totally confident in my very large investment here.
(4)
(0)Scroll down for more posts ▼
